SCHEMBL7704946

SCHEMBL7704946

COc1ccc(CN(Cc2ccc3c(c2)NC(N)=C(C)O3)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
USP2 O75604 3/20 0.35
TSHR P16473 3/20 0.35
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 2/20 0.35
NR1D1 P20393 1/20 0.35
POLB P06746 1/20 0.35
HPGD P15428 1/20 0.35
TSPO P30536 1/20 0.34
SLC2A1 P11166 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
KLK1 P06870 1/20 0.33
CHEK1 O14757 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704872 0.92 HSD17B2 (0.38) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7708189 0.91 HDAC3 (0.37) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711366 0.91 HDAC1 (0.37) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7704910 0.90 HDAC1 (0.45) ALDH1A1NPSR1HDAC3HDAC1HDAC2
SCHEMBL7708353 0.89 GRM2 (0.37) ALDH1A1NPSR1HDAC3HDAC1HDAC2
SCHEMBL7704965 0.89 HDAC3 (0.36) ALDH1A1NPSR1HDAC3HDAC1HDAC2
SCHEMBL7711328 0.89 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2L3MBTL1
SCHEMBL7713435 0.87 HDAC1 (0.34) HDAC3HDAC1HDAC2NCOR2
SCHEMBL7710748 0.87 CA2 (0.35) NPSR1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711458 0.86 HDAC3 (0.33) HDAC3HDAC1HDAC2NCOR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed